Fri, Aug 1, 2014, 7:53 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Galena Biopharma, Inc. Message Board

  • opus111arietta opus111arietta Dec 1, 2013 5:03 PM Flag

    Bio22 isn't that far off

    He brings some good points and betting the house on a small cap biotech like GALE is the dumbest thing an investor could do. Caution should be the word here on this board. Biotech failures are much more common then successes. That is a fact.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • dens214 Dec 1, 2013 9:09 PM Flag

      No risk--no reward. If you suspect somebody doesn't know that, please message them individually. This whole message thread is a waste of energy. Mine included.

    • Nobody denies that developmental small cap biopharma are high risk investments.

      Gale is no longer a pure developmental biotech with no revenue. It has Abstral (an FDA approval product) and will stabilize its future financial position. You need to learn more and have more confidence on the science of NeuVax. You also need to know the outstanding results of NeuVax Phase 1 & 2. For Phase 3, the FDA took part in the trial designs and give a Special Protocol Assessment status to NeuVax. I am holding a modest position in Gale and I trust that NeuVax will make obtain FDA approval.

      My risk? If NeuVax does not reach FDA approval and Gale's share price may drop back to 50 cents per share. Then what? I can afford to lose all of my Gale investment.

      Thank you for your cautious advice!

      Strong buy and hold Gale shares!!!

      • 2 Replies to stockwatcher888
      • Dummy at it again: " For Phase 3, the FDA took part in the trial designs and give a Special Protocol Assessment status to NeuVax." Of course you want to FDA to take part in trial designs DUMMY. That is standard procedure. It doesn't mean it will succeed. Recent example so you can do a Google search and learn something. Google "Amarin" and "Anchor" and "FDA SPA". Trying to keep you updated on current events newbie.

        Not sure if you old timer knows about "Google" but it is a search engine. The equivalent for your time was Alta Vista or WebCrawler.

      • GALE success later on is solely based on Neuvax. Abstral is a very little part of why people are interested or investing in GALE. That is fact. If any bad news about Neuvax is revealed I guarantee investors will flee as fast as they came. Revenues that may come from Abstral will have little affect on GALE and certainly is not the focus of GALE management.

        Being long here makes zero sense. What makes sense is trying to understand Neuvax and why it may work and get FDA approval. Nothing else matters nor makes sense in regards to this company. If u doubt that for one second then u are not understanding the risk here or why u saying u r long is plain foolish.


    • You are just as far off as he is. God, due some DD.

      Sentiment: Strong Buy

      • 1 Reply to indulgeron
      • Its not just about doing DD. Its about realizing and respecting the risk that comes with all stocks and especially small biotech that yet have a major source of revenues. Their sole success depends on the FDA and no one has a crystal ball as to the FDA and why and how they make their decisions. Everything can appear to be going great and then, BAM, the FDA decides against a particular product for a reason that no one expects.

        Many on this board act as if GALE is untouchable and their success is for certain. Nothing further from the truth is reality. I think GALE is a great company and I like their management team and the progress they have made. I have shares for that reason. But I am certainly am very cautious and very weary of the affect any bad news about Neuvax would have on the PPS. To ignore this high risk would be foolish and irresponsible of me as an investor.

        With all the recent major blows to biotech companies recently (DDXS, SRPT, ARIA), to name a few, one should consider the risk even more in such companies, not less.


2.80-0.04(-1.41%)Aug 1 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.